4D Molecular Therapeutics Q2 net loss widens to $54.7 mln

4D Molecular Therapeutics

11/08/2025 13:09

Overview

4D Molecular Therapeutics Q2 net loss widens to $54.7 mln from $35.0 mln

R&D expenses rise due to Phase 3 trial initiation for 4D-150 in wet AMD

Co streamlines organization, reducing workforce by 25% to extend cash runway

Outlook

4DMT expects 4FRONT-1 data in H1 2027, accelerated from H2 2027

Company initiated 4FRONT-2 trial ahead of schedule

4DMT expects cash to fund operations into 2028

Company aligns with FDA and EMA for Phase 3 trial approval

Result Drivers

ACCELERATED TRIALS - Rapid enrollment in 4FRONT-1 trial for 4D-150 in wet AMD allows for accelerated data readout to H1 2027

STREAMLINED OPERATIONS - Workforce reduction by 25% to focus on late-stage execution and extend cash runway into 2028

POSITIVE TRIAL RESULTS - 60-week data from SPECTRA trial in DME shows favorable tolerability and sustained treatment benefits

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$15,000
Q2 Net Income
-$54.66 mln
Q2 Basic EPS
-$0.98
Q2 Operating Expenses
$59.47 mln
Q2 Operating Income
-$59.46 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $30.00, about 81.2% above its August 8 closing price of $5.63

Press Release: ID:nGNX3tW5c8

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)